Ex-Pfiz­er CEO's start­up Cen­trex­ion gets $67M for PhI­II painkiller

Cen­trex­ion Ther­a­peu­tics, a Boston-based start­up led by ex-Pfiz­er CEO Jeff Kindler, just raised $67 mil­lion to bring its painkiller drug in­to Phase III tri­als. If it works, the treat­ment should ap­pease reg­u­la­tors con­cerned with ad­dic­tion prob­lems, as the drug is a non-opi­oid and non-steroid way to treat pain.

“I be­lieve the opi­oid cri­sis is a prod­uct of a pain cri­sis,” Kindler tells me. “Non-ad­dic­tive, non-steroidal al­ter­na­tives to opi­oids are an enor­mous need.”

The new Se­ries D cash will move Cen­trex­ion’s lead pro­gram for os­teoarthri­tis-re­lat­ed knee pain in­to Phase III tri­als. The drug pro­gram, called CN­TX-4975, is a syn­thet­ic, ul­tra-po­tent and pure form of cap­saicin, the ac­tive in­gre­di­ent in chili pep­pers. Cap­saicin has long been used as a top­i­cal anal­gesic, but Kindler says the com­pa­ny has de­vel­oped a patent­ed in­jec­tion pro­ce­dure that al­lows the meds to be de­liv­ered di­rect­ly to the site of pain.

The drug tar­gets the TR­PV1 re­cep­tor and aims to de­ac­ti­vate pain fibers that send pain sig­nals from the knee straight to the brain. Kindler is quick to point out that “turns that sig­nal off with­out af­fect­ing oth­er lo­cal pain fibers that af­fect things like touch, pres­sure, and po­si­tion.” That means they’re not see­ing off tar­get ef­fects, like with sys­temic ther­a­pies, he said.

A sin­gle in­jec­tion should work for six months, un­til the fibers re­gen­er­ate to start flash­ing those sig­nals again.

Sara Nay­eem

CN­TX-4975 will en­ter two Phase III tri­als in this in­di­ca­tion – one that tests a sin­gle dose, and one that looks at a re­peat dose af­ter month six. The drug is al­so Phase III-ready as a vet­eri­nary drug for ca­nine OA pain, and for Mor­ton’s neu­ro­ma pain. How­ev­er, Kindler said the new fi­nanc­ing round was specif­i­cal­ly for knee OA pain.

For the new round, New En­ter­prise As­so­ci­ates led the fi­nanc­ing with par­tic­i­pa­tion from new and ex­ist­ing in­vestors, in­clud­ing Quan Cap­i­tal and Ar­row­Mark Part­ners, among oth­ers. As part of the fi­nanc­ing, Cen­trex­ion named NEA part­ner Sara Nay­eem and Quan’s man­ag­ing di­rec­tor Stel­la Xu to its board of di­rec­tors.

Stel­la Xu

Cen­trex­ion, found­ed in 2013, is a still a rather small start­up em­ploy­ing on­ly 12 peo­ple in Boston. The com­pa­ny has man­aged to re­cruit a board and C-suite stocked with heavy­weights. Oth­er than Kindler him­self, who was chair­man and CEO of Pfiz­er be­fore tak­ing the helm at Cen­trex­ion, the team al­so in­cludes Ran­dall Stevens, who played a key role in get­ting five ap­proved drugs to mar­ket (in­clud­ing Rit­ux­an), and Sol Bar­er, who helped found Cel­gene.

“We’ve built an ex­tra­or­di­nary team with a track record of de­vel­op­ment and com­mer­cial­iza­tion,” Kindler said. “In our com­pa­ny’s fair­ly short ex­is­tence, we’ve man­aged to build the largest pipeline of non-opi­oid and non-steroidal pain treat­ments in the in­dus­try.”

Oth­er than CN­TX-4975, Cen­trex­ion al­so has sep­a­rate pro­grams in in­flam­ma­to­ry, neu­ro­path­ic, and su­per­fi­cial pain.

Alice Shaw, Lung Cancer Foundation of America

Top ALK ex­pert and can­cer drug re­searcher Al­ice Shaw bids adieu to acad­e­mia, hel­lo to No­var­tis

Jay Bradner has recruited a marquee oncology drug researcher into the ranks of the Novartis Institutes for BioMedical Research. Alice Shaw is jumping from prestigious posts intertwined through Mass General, Harvard and Dana-Farber to take the lead of NIBR’s translational clinical oncology group.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron, GSK's president of R&D and CSO, speaks to Endpoints News founder and editor John Carroll in London at Endpoints' #UKBIO19 summit on October 8, 2019

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

Last week I had a chance to sit down with Hal Barron at Endpoints’ #UKBIO19 summit to discuss his views on R&D at GSK, a topic that has been central to his life since he took the top research post close to 2 years ago. During the conversation, Barron talked about changing the culture at GSK, a move that involves several new approaches — one of which involves celebrating their setbacks as they shift resources to the most promising programs in the pipeline. Barron also discussed his new alliances in the Bay Area — including his collaboration pact with Lyell, which we covered here — frankly assesses the pluses and minuses of the UK drug development scene, and talks about his plans for making GSK a much more effective drug developer.

This is one discussion you won’t want to miss. Insider and Enterprise subscribers can log-in to watch the video.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Med­ical an­i­ma­tion: Mak­ing it eas­i­er for the site and the pa­tient to un­der­stand

Medical animation has in recent years become an increasingly important tool for conveying niche information to a varied audience, particularly to those audiences without expertise in the specialist area. Science programmes today, for example, have moved from the piece-to-camera of the university professor explaining how a complex disease mechanism works, to actually showing the viewer first-hand what it might look like to shrink ourselves down to the size of an ant’s foot, and travel inside the human body to witness these processes in action. Effectively communicating a complex disease pathophysiology, or the novel mechanism of action of a new drug, can be complex. This is especially difficult when the audience domain knowledge is limited or non-existent. Medical animation can help with this communication challenge in several ways.
Improved accessibility to visualisation
Visualisation is a core component of our ability to understand a concept. Ask 10 people to visualise an apple, and each will come up with a slightly different image, some apples smaller than others, some more round, some with bites taken. Acceptable, you say, we can move on to the next part of the story. Now ask 10 people to visualise how HIV’s capsid protein gets arranged into the hexamers and pentamers that form the viral capsid that holds HIV’s genetic material. This request may pose a challenge even to someone with some virology knowledge, and it is that inability to effectively visualise what is going on that holds us back from fully understanding the rest of the story. So how does medical animation help us to overcome this visualisation challenge?

Flu Virus (Source: CDC)

FDA ex­pands Xofluza ap­proval as Roche strug­gles to catch loom­ing flu mar­ket

As a potentially powerful flu season looms, so does a big test for Roche and its new flu drug, Xofluza. The Swiss giant just got a small boost in advance of that test as the FDA expanded Xofluza’s indication to include patients at high risk of developing flu-related complications.

Xofluza (baloxavir marboxil) was approved last October in the US, the first landmark flu drug approval in 20 years and a much-needed green light for a company that had watched its leading flu drug Tamiflu get eaten alive by generics. Like its predecessor, the pill offered a reduction in flu symptoms but not a cure.

Mi­rati preps its first look at their KRAS G12C con­tender, and they have to clear a high bar for suc­cess

If you’re a big KRAS G12C fan, mark your calendars for October 28 at 4:20 pm EDT.

That’s when Mirati $MRTX will unveil its first peek at the early clinical data available on MRTX849 in presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Mirati has been experiencing the full effect of a rival’s initial success at targeting the G12C pocket found on KRAS, offering the biotech some support on the concept they’re after — and biotech fans a race to the top. Amgen made a big splash with its first positive snapshot on lung cancer, but deflated sky-high expectations as it proved harder to find similar benefits in other types of cancers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

The FDA will hus­tle up an ex­pe­dit­ed re­view for As­traZeneca’s next shot at a block­buster can­cer drug fran­chise

AstraZeneca paid a hefty price to partner with Daiichi Sankyo on their experimental antibody drug conjugate for HER2 positive breast cancer. And they’ve been rewarded with a fast ride through the FDA, with a straight shot at creating another blockbuster oncology franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Sean Parker, AP

Sean Park­er helps cre­ate a CRISPRed cell ther­a­py 2.0 play — and he’s got a high-pro­file set of lead­ers on the team

You can rack up one more high-profile debut effort in the wave of activity forming around cell therapy 2.0. It’s another appealing Bay Area group that’s attracted some of the top hands in the business to a multi-year effort to create a breakthrough. And they have $85 million in hand to make that first big step to the clinic.

Today it’s Ken Drazan and the team at South San Francisco-based ArsenalBio that are coming from behind the curtain for a public bow, backed by billionaire Sean Parker and a collection of investors that includes Beth Seidenberg’s new venture investment operation based in LA.
Drazan — a J&J Innovation vet with a long record of entrepreneurial endeavors — exited the stage in 2018 when his last mission ended as he stepped aside as president of Grail. It wasn’t long, though, before he was helping out with a business plan for ArsenalBio that revolved around the work of a large group of interconnected scientists supported by the Parker Institute for Cancer Immunology.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

CSL ac­cus­es ri­val Pharm­ing of par­tic­i­pat­ing in a scheme to rip off IP on HAE while re­cruit­ing se­nior R&D staffer

Pharming has landed in the middle of a legal donnybrook after recruiting a senior executive from a rival R&D team at CSL. The Australian pharma giant slapped Pharming with a lawsuit alleging that the Dutch biotech’s new employee, Joseph Chiao, looted a large cache of proprietary documents as he hit the exit. And they want it all back.
Federal Judge Juan Sanchez in the Eastern District Pennsylvania court issued an injunction on Tuesday prohibiting Chiao from doing any work on HAE or primary immune deficiency in his new job and demanding that he return any material from CSL that he may have in his possession. And he wants Pharming to tell its employees not to ask for any information on the forbidden topics.
For its part, Pharming fired off an indignant response this morning denying any involvement in extracting any kind of IP from CSL, adding that it’s cooperating in the internal probe that CSL has underway.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Eli Lil­ly’s first PhI­II show­down for their $1.6B can­cer drug just flopped — what now?

When Eli Lilly plunked down $1.6 billion in cash to acquire Armo Biosciences a little more than a year ago, the stars seemed aligned in its favor. The jewel in the crown they were buying was pegilodecakin, which had cleared the proof-of-concept stage and was already in a Phase III trial for pancreatic cancer.

And that study just failed.

Lilly reported this morning that their cancer drug flopped on overall survival when added to FOLFOX (folinic acid, 5-FU, oxaliplatin), compared to FOLFOX alone among patients suffering from advanced pancreatic cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.